Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“We also have contract manufacturing arrangements with AGC Biologics and the Polypeptide Group to provide contract development and manufacturing services, supplying us with large-scale production of Matrix-M™ adjuvant.”
FILING10-K0001000694-26-000007cik 0001000694
“We also have contract manufacturing arrangements with AGC Biologics and the Polypeptide Group to provide contract development and manufacturing services, supplying us with large-scale production of Matrix-M™ adjuvant.”
FILING10-K0001000694-26-000007cik 0001000694
“In August 2022, we and SII entered into an influenza license agreement under which we granted SII licenses to develop, manufacture, and commercialize certain vaccine products including influenza vaccine products and influenza and coronavirus combination vaccine products ("CIC") and are obligated to purchase up to approximately $34 million of certain raw materials under related agreements with SII.”
FILING10-K0001000694-26-000007cik 0001000694
“In May 2024, we and SLS entered into a supply agreement (the "SLS Supply Agreement") under which SLS agreed to supply us with antigen drug substance and finished COVID-19 Vaccine doses.”
FILING10-K0001000694-26-000007cik 0001000694
“Under the Amended Takeda CLA, Takeda will continue to purchase our Matrix-M™ adjuvant to manufacture doses of finished COVID-19 Vaccine with updated adjuvant forecast and other supply terms.”
FILING10-K0001000694-26-000007cik 0001000694
“For example, in December 2024, we entered into an amendment to the Australia APA pursuant to which, among other things, we acknowledged the cancellation by Australia of the delivery of certain doses of our COVID-19 Vaccine scheduled for delivery between the fourth quarter of 2023 and the fourth quarter of 2025 and we agreed to credit approximately $31 million of the advanced payment paid by Australia to us against outstanding invoices and invoices for the future delivery of approximately three million doses of COVID-19 Vaccine without requiring additional cash payments.”
FILING10-K0001000694-26-000007cik 0001000694
“We had an APA with His Majesty the King in Right of Canada as represented by the Minister of Public Works and Government Services, as successor in interest to Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works and Government Services (the "Canadian government"), for the purchase of doses of COVID-19 Vaccine (as amended, the "Canada APA").”
FILING10-K0001000694-26-000007cik 0001000694
“As part of the New Zealand Settlement Agreement, we paid Pharmac a refund of previously received upfront payments of $4.0 million.”
FILING10-K0001000694-26-000007cik 0001000694
“We have an agreement with SII related to its manufacture of R21/Matrix-M™ adjuvant malaria vaccine under which SII purchases our Matrix-M™ adjuvant for use in development activities at cost and for commercial purposes at a tiered commercial supply price, and pays a royalty in the single- to low-double digit range based on vaccine sales for a period of 15 years after the first commercial sale of the vaccine in each country.”
FILING10-K0001000694-26-000007cik 0001000694
“We agreed to supply SLS with all Matrix-M™ adjuvant needed to manufacture finished COVID-19 Vaccine doses.”
FILING10-K0001000694-26-000007cik 0001000694
“These obligations include $133.9 million related to an APA with the Commonwealth of Australia ("Australia") for the purchase of doses of COVID-19 Vaccine (the "Australia APA"), $225.0 million under our APA with the Vaccine Alliance ("Gavi"), and $73.3 million related to various other countries.”
FILING10-K0001000694-26-000007cik 0001000694
“C o-exclusive licensing agreement with Novavax. The terms of the agreement include (i) a co-exclusive license to co- commercialize Novavax's current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements and in India, Japan, and South Korea, where Novavax has existing partnership agreements); (ii) a sole license to Novavax's adjuvanted COVID-19 vaccine for use in combination with Sanofi's flu vaccines; and (iii) a non- exclusive license to use the Matrix-M adjuvant in vaccine products. Novavax received an upfront payment of $ 500 million and could receive up to $ 700 million contingent on attainment of development, regulatory and commercialization milestones, representing up to $1.2 billion in total.”
FILING20-F0001628280-26-008403cik 0001121404disclosed by SNY
“In January 2026, we entered into a License and Option Agreement with Pfizer Inc. ("Pfizer") for use of our Matrix-M™.”
FILING10-K0001000694-26-000007cik 0001000694
“In March 2025, we received a communication (the "Notice") terminating, with immediate effect, the Canada APA on the basis of us not receiving regulatory approval for our COVID-19 Vaccine using bulk antigen produced at Biologics Manufacturing Centre Inc. on or before December 31, 2024, pursuant to the terms of the Canada APA.”
FILING10-K0001000694-26-000007cik 0001000694
“We had an APA with His Majesty the King in Right of Canada as represented by the Minister of Public Works and Government Services, as successor in interest to Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works and Government Services (the "Canadian government"), for the purchase of doses of COVID-19 Vaccine (as amended, the "Canada APA").”
FILING10-K0001000694-26-000007cik 0001000694
Watchlist prices, news filtered to it, and its next report on your desk.
Novavax Inc has 5 disclosed suppliers and 10 disclosed customers. Each one is named in an SEC filing, either Novavax Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Novavax Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Prev close 9.24 · gapped above the open, then crossed back over prior close. High/low 9.53 at 8:00 am ET, 9.17 at 12:00 pm ET.
NVAX (Novavax Inc) has 5 disclosed suppliers and 10 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: SNY −2.03%, in industrials & materials.